Olema Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
OLMA Nasdaq 2830 olema.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Olema Pharmaceuticals, Inc.

The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology - Oct 19th, 2026 6:00 am
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month - Oct 16th, 2026 6:45 am
SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight - Oct 5th, 2026 8:31 am
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 2nd, 2026 2:30 pm
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results - Sep 14th, 2026 6:10 am
Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump - Sep 14th, 2026 5:41 am
Olema Oncology to Participate in Upcoming Investor Conferences - Aug 31st, 2026 2:30 pm
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer - Aug 13th, 2026 5:00 am
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results - Aug 10th, 2026 2:01 pm
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story? - Jun 30th, 2026 6:07 am
How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet - Jun 17th, 2026 9:17 am
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer - May 26th, 2026 5:00 am
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap - May 25th, 2026 1:05 pm
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting - May 21st, 2026 3:00 pm
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - May 20th, 2026 11:00 am